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New Opportunities and Challenges for Clinical
Application of mIBG Imaging*
Bertram Pitt, MD
Ann Arbor, MichiganMyocardial meta-iodobenzylguanidine iodine-123
(123I-mIBG) imaging has been shown to provide
prognostic information on patients with chronic
heart failure (HF) and a reduced left ventricular
ejection fraction (HFREF), in patients with HF
and a normal left ventricular ejection fraction
(HFNEF), in patients post-myocardial infarction,
See page 959
and in patients with diabetes mellitus. A recent
multicenter study of 123I-mIBG in approximately
1,000 patients with New York Heart Association
functional class II to III HFREF found the heart
/mediastinum (H/M) ratio of 123I-mIBG to provide
information on the risk of death independent of
that provided by left ventricular ejection fraction or
determination of B-type natriuretic peptide (1). A
decrease in 123I-mIBG H/M independently pre-
dicted death due to both progressive HF and
sudden cardiac death. 123I-mIBG has also been
shown to be of value in evaluating the effectiveness
of various therapeutic interventions in patients with
HF, such as aldosterone blockade, improving car-
diac norepinephrine uptake and therefore predict-
ing an improvement in long-term cardiac outcomes.
In this issue of iJACC, Martins et al. (2) explore
the utility of myocardial 123I-mIBG imaging to
detect asymptomatic family members of patients
with familial dilated cardiomyopathy (FDCM).
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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Medicine, Cardiovascular Center, Ann Arbor, Michigan. Dr. Pitt is a
consultant for GE HealthCare, Pfizer, Novartis, Merck, Takeda, Astra-
Zeneca, Boehringer Ingelheim, Forrest Laboratories, and Bayer; has stock
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from Medtronic, Novartis, Bayer, and Abbott.They evaluated 45 members of 23 families with
FDCM with both the H/M and the myocardial
washout rate (WR) of 123I-mIBG as well as
2-dimensional echocardiography, electrocardiogra-
phy, B-type natriuretic peptide, and, in 40 of 45
individuals, cardiac magnetic resonance. Of interest
was their finding of an abnormally high 123I-mIBG
WR in 11 (69%) of the subset of 16 family members
with normal left ventricular function. These 11
patients with an abnormal myocardial 123I-mIBG
WR included 5 with reverse remodeling, 4 of 5
identified carriers of the familial trait, and 2 rela-
tives with normal echocardiograms and unknown
carrier state. In this subset of individuals with
normal left ventricular function at risk of the
development of FDCM, they did not find any
correlation between 123I-mIBG H/M or WR and
left ventricular function or mass. However, there
was a significant correlation with parameters of
heart rate variability relating to increased sympa-
thetic nervous system activity, suggesting an in-
creased long-term cardiovascular risk. The small
number of patients and the relatively short
follow-up precluded an evaluation of the prognostic
value of the finding of an abnormal myocardial WR
with myocardial 123I-mIBG imaging in asymptom-
atic individuals with normal left ventricular func-
tion at risk of the development of FDCM. The
promise of the early detection of asymptomatic
individuals with normal left ventricular function at
risk of the development of FDCM holds the
promise for the early application of therapy to
prevent its development and or consequences, such
as sudden cardiac death or progressive HF. A far
larger number of patients will, however, need to be
studied to determine the prognostic value of the
finding of an abnormal 123I-mIBG WR in these
asymptomatic individuals with normal left ventric-
ular function and further information on the time
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Editorial Comment
965ourse from detection of an abnormal WR to the
evelopment of HF will be needed as well. How-
ver, even if future studies demonstrate that an
bnormal 123I-mIBG WR predicts the subsequent
evelopment of HF, the application of this tech-
ique into clinical practice remains uncertain. 123I-
IBG requires cyclotron production, and therefore
yocardial imaging with this agent will likely be
elatively expensive. To justify its clinical applica-
ion in the coming era of increased cost contain-
ent of health care resources, myocardial 123I-
IBG will not only need to be shown to detect early
isease, but the net effect of the myocardial imaging
nd the therapeutic approach elicited by the finding
f an abnormal WR will also need to be cost-
ffective.
Similarly, the finding that myocardial 123I-mIBG
maging provides independent prognostic informa-
ion in patients with HF, in post-myocardial infarc-
ion, and in diabetes mellitus, although of interest,
s unlikely in and of itself to be sufficient to justify
ts adoption into clinical practice unless the infor-
ation that it provides results in a change in clinical
utcomes and that the net cost of the 123I-mIBG
yocardial imaging and the strategy evoked by the
nformation that it provides can be shown to be
ost-effective. Although the finding of a decreased
23I-mIBG H/M in a patient with HFREF sug-
esting an increased risk of cardiac death might
rompt optimization of medical therapy such as an
ncrease in the dose of an angiotensin-converting
nzyme inhibitor or a beta-adrenergic blocking
gent, it might not be cost-effective in the long run
ecause one might argue that all patients with HF
hould be treated with target or maximally tolerated
oses of guideline-recommended therapy such as
ngiotensin-converting enzyme inhibitors and an-
iotensin receptor blocking agents, beta-adrenergic
locking agents, and aldosterone blocking agents.diac events in heart failure. Results of 123 and cardiac adrnformation provided by a normal or abnormal
23I-mIBG myocardial image could be of value in
eciding on the use of high-risk/high-cost strate-
ies such as an implantable cardiac defibrillator,
ardiac resynchronization therapy, and stem cell
nd/or gene therapy. For example, the finding of a
ormal H/M and myocardial WR in a patient with
FREF and an indication for an implantable
ardiac defibrillator might avoid implantation of
his device, which, although effective in reducing
eath, is often not required and therefore often not
sed in the most cost-efficient manner. Conversely,
he finding of an abnormal 123I-mIBG H/M and or
yocardial WR in a patient with HFNEF suggest-
ng an increased risk of cardiac death might prompt
onsideration of implantation an implantable car-
iac defibrillator, cardiac resynchronization therapy,
r both. It would, however, be necessary to more
learly understand the confidence limits of the
alse-negative and false-positive implications of
hese findings before deciding to withhold poten-
ially life-saving therapy on the basis of a normal
23I-mIBG myocardial image or to use a high-cost/
igh-risk strategy due to an abnormal image sug-
esting an increased risk of cardiac death in a
atient in whom it is not otherwise indicated.
learly, relatively high-cost techniques such as
23I-mIBG imaging, although holding great prom-
se to improve the early detection of cardiovascular
isease and allowing the selection of low- and
igh-risk subsets to more appropriately apply high-
isk/high-cost therapeutic strategies, face new chal-
enges in the coming era of cost containment in
ealth care resources.
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